Coya Therapeutics (COYA) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Coya Therapeutics is the larger company by market cap ($99.7 million vs $93.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | PLYX |
|---|---|---|
| Share price | $4.25 | $1.88 |
| Market cap | $99.70M | $93.71M |
| 1-day change | -2.07% | -3.59% |
| YTD return | -26.72% | — |
| 1-year return | -33.18% | — |
| EPS (TTM) | $-1.07 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | — |
| Revenue growth (YoY) | +123.57% | — |
| Net income (latest FY) | $-21.23M | $-8.98M |
| Operating margin | -283.87% | — |
| Net margin | -267.14% | — |
| 52-week high | $7.55 | $48.91 |
| 52-week low | $3.71 | $1.85 |
| Distance from 52-week high | -43.71% | -96.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +257.88% | +298.94% |
| Average volume | 140.71K | 70.79K |
| Shares outstanding | 23.46M | 49.85M |
| Employees | 8 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
COYA vs PLYX FAQ
Which is bigger, Coya Therapeutics or Polaryx Therapeutics?
Coya Therapeutics (COYA) is larger, with a market capitalization of $99.70M compared with $93.71M for Polaryx Therapeutics (PLYX).
Are Coya Therapeutics and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.